For most women, getting a mammogram every two years is not only acceptable but is the schedule recommended by the nation’s leading preventive health authority. The U.S. Preventive Services Task Force specifically recommends biennial (every other year) screening mammography for women aged 40 to 74. That said, some organizations recommend annual screening during certain age ranges, and your personal risk factors can shift which interval makes more sense for you.
What the Major Guidelines Say
The two most influential sets of screening guidelines in the U.S. take slightly different positions on frequency, which is part of why many women feel confused.
The USPSTF, whose recommendations drive insurance coverage policy, says every two years from age 40 through 74 is the right cadence for women at average risk. This is their standard recommendation for the general population. The American Cancer Society takes a more layered approach: it recommends annual mammograms starting at age 45 (with the option to begin at 40), then says women 55 and older can switch to every other year if they prefer, or continue annually. Both organizations agree that biennial screening is a reasonable choice, particularly for women in their mid-50s and beyond.
The difference between these guidelines comes down to how each group weighs the tradeoff between catching cancers slightly earlier and exposing women to the downsides of more frequent screening, like false alarms and unnecessary biopsies.
How Biennial Screening Compares to Annual
The core question behind this search is whether spacing mammograms two years apart misses too much. The evidence suggests the mortality benefit of screening does not dramatically change when you go from annual to biennial intervals for average-risk women. The USPSTF landed on every two years precisely because the data showed it preserved most of the life-saving benefit while significantly reducing harms.
Those harms are real and measurable. Over a 10-year period starting at age 40, women who screen annually have a 61% cumulative chance of getting at least one false-positive result, meaning the mammogram flags something suspicious that turns out not to be cancer. For women screening every two years, that number drops to 42%. The rate of unnecessary biopsies also falls, from about 7% over a decade with annual screening to roughly 5% with biennial screening. A false positive doesn’t just mean an extra appointment. It often means weeks of anxiety, additional imaging, and sometimes a needle biopsy, all for a finding that was never cancer.
When Annual Screening May Be Worth It
Every-two-year screening works well as a default for average-risk women, but certain factors can tip the balance toward annual mammograms. The most important ones are your personal and family history of breast cancer, whether you carry genetic mutations like BRCA1 or BRCA2, and your breast density.
Breast density matters because dense tissue can both obscure cancers on a mammogram and independently raises your risk of developing breast cancer. The National Comprehensive Cancer Network recommends that women with very dense breasts begin annual screening mammography no later than age 40. If your mammogram report has ever noted heterogeneously dense or extremely dense breast tissue (your imaging center is required to tell you), it’s worth having a conversation about whether annual screening or supplemental imaging like breast MRI makes sense for you.
Women in their 40s also face a slightly different calculus. Breast cancers in younger women tend to grow faster, which is one reason the American Cancer Society recommends annual screening from 45 to 54. If you’re in your 40s and choosing between annual and biennial, your individual risk profile matters more than it does for a 60-year-old at average risk.
Screening After Age 74
The USPSTF recommendation covers women through age 74 and doesn’t extend beyond that, not because screening is harmful at older ages but because there isn’t enough evidence to make a firm population-wide recommendation. For women 75 and older, the decision depends heavily on overall health and life expectancy.
One important consideration at older ages is overdiagnosis: detecting a cancer through screening that would never have caused symptoms or shortened a woman’s life. A study analyzed by the National Cancer Institute estimated that among women aged 70 to 74 diagnosed with breast cancer on a screening mammogram, roughly 31% were overdiagnosed. That estimate rose to 47% for women aged 75 to 84 and exceeded 50% for women with a life expectancy under five years. Overdiagnosis leads to treatment (surgery, radiation, hormonal therapy) for a cancer that didn’t need treating, which carries its own physical and emotional costs.
Insurance Coverage for Either Schedule
Under the Affordable Care Act, most health insurance plans must cover screening mammography without any copay, coinsurance, or deductible. Federal guidelines supported by the Health Resources and Services Administration state that screening should occur “at least biennially and as frequently as annually,” meaning insurers are required to cover mammograms at either interval for women in the recommended age range. If you choose annual screening, you should not face out-of-pocket costs. If you choose biennial, same applies. The coverage question should not drive your decision about frequency.
Making the Decision
If you’re at average risk, with no family history, no known genetic mutations, and no notably dense breast tissue, every two years is a well-supported screening interval that catches the vast majority of clinically significant cancers while sparing you a meaningful number of false alarms and follow-up procedures. It is the approach recommended by the USPSTF for all women aged 40 to 74.
If you have risk factors that put you above average, annual screening or even supplemental imaging beyond standard mammography may offer additional protection worth the tradeoffs. The right interval is ultimately a personal decision shaped by your risk level, your comfort with uncertainty, and how you weigh the possibility of a false alarm against the possibility of a delayed diagnosis.